ClinicalTrials.gg
TerminatedNCT02971839Updated Aug 26, 2020Results posted

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

A Phase 2 interventional study of VX-561 and Placebo in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-26.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Why this study was terminated
Decision by Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
79th of 84
11 · median 70
Started
2016
with 9 others
Phase 2
17 of 84
none open now
Registered
45th of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 79th largest by enrollment, is one of 10 that started in 2016, is one of 17 in phase 2, and was the 45th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of CTP-656 in patients with cystic fibrosis (CF) who have a cystic fibrosis transmembrane conductance regulator (CFTR) gating mutation.

Read the detailed description

This is a randomized, parallel-group, double-blind, placebo controlled multicenter study to evaluate the safety and efficacy of CTP-656 in CF patients with CFTR gating mutations, compared to Kalydeco, for a total of 28 days. Subjects will be randomized to receive either double-blind CTP-656 or placebo, or open-label Kalydeco.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Has a confirmed diagnosis of CF with at least one allele of the following CFTR gating mutations: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R.
  • Has been stable on Kalydeco therapy for at least 3 months prior to screening
  • Has ≥ 60% of predicted normal for age, sex, and height at screening and baseline (Day 1) assessments
  • Weighs at least 40 kg at screening
  • Patients of either gender and women of must be willing to use a medically highly effective form of during the treatment period and 30 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Acute upper respiratory infection or lower respiratory infection, pulmonary exacerbation, or changes in therapy within 4 weeks of study treatment
  • Uncontrolled type 2 diabetes, or uncontrolled CF-related diabetes
  • History of or chronic active infection
  • History of pulmonary tuberculosis, non-tuberculosis mycobacterial infections or allergic bronchopulmonary aspergillosis (ABPA) treated during screening or within 2 years prior to screening
  • Colonization with B. cenocepacia, B. dolosa, B. multivorans, and/or M. abcessus within 2 years prior to Screening
  • Abnormal liver function
  • History of abnormal renal function
  • History of prolonged > 450 msec for males or QTcF > 470 msec for females
  • History of solid organ or hematological transplantation
  • Using any inhibitor or inducer of cytochrome P450/3A during the study or within 30 days of screening
  • Women who are pregnant or lactating, or have plans to become pregnant during the study or within 1 month following the last dose
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    VX-561 20 mg

    Drug: VX-561

  • Experimental
    VX-561 100 mg

    Drug: VX-561

  • Experimental
    VX-561 150 mg

    Drug: VX-561

  • Active comparator
    Ivacaftor

    Drug: IVA

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugVX-561

    Also known as: CTP-656

  • DrugPlacebo
  • DrugIVA

    Also known as: ivacaftor; VX-770, Kalydeco

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Sweat Chloride at Day 28

    Time frame: From baseline at Day 28

Secondary outcomes

  1. Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28

    Time frame: From baseline at Day 28

  2. Change From Baseline in Cystic Fibrosis Questionnaire-Respiratory Domain (CFQ-R) at Day 28

    Time frame: From baseline at Day 28

07

Results

Posted Aug 26, 2020

Participant flow

Participant flow — Overall Study
MilestoneVX-561 20 mgVX-561 100 mgVX-561 150 mgPlaceboIvacaftor
Started22223
Completed22223
Not completed00000

Outcome measures

PrimaryChange From Baseline in Sweat Chloride at Day 28
Time frame:
From baseline at Day 28

No measurements were reported for this outcome.

SecondaryChange From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Day 28
Time frame:
From baseline at Day 28

No measurements were reported for this outcome.

SecondaryChange From Baseline in Cystic Fibrosis Questionnaire-Respiratory Domain (CFQ-R) at Day 28
Time frame:
From baseline at Day 28

No measurements were reported for this outcome.

Adverse events

Collected over Day 1 up to Day 35. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VX-561 20 mg0/2 (0%)0/2 (0%)2/2 (100%)
VX-561 100 mg0/2 (0%)0/2 (0%)2/2 (100%)
VX-561 150 mg0/2 (0%)0/2 (0%)1/2 (50%)
Placebo0/2 (0%)0/2 (0%)2/2 (100%)
Ivacaftor0/3 (0%)0/3 (0%)1/3 (33.3%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventVX-561 20 mgVX-561 100 mgVX-561 150 mgPlaceboIvacaftor
CoughRespiratory, thoracic and mediastinal disorders0/20/21/22/20/3
Sputum increasedRespiratory, thoracic and mediastinal disorders0/20/20/22/20/3
Paranasal sinus hypersecretionRespiratory, thoracic and mediastinal disorders0/20/21/21/20/3
DyspnoeaRespiratory, thoracic and mediastinal disorders0/20/20/21/20/3
Increased bronchial secretionRespiratory, thoracic and mediastinal disorders1/20/20/20/20/3
Nasal congestionRespiratory, thoracic and mediastinal disorders1/20/20/20/20/3
Nasal oedemaRespiratory, thoracic and mediastinal disorders1/20/20/20/20/3
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/20/20/20/20/3
Pharyngeal erythemaRespiratory, thoracic and mediastinal disorders1/20/20/20/20/3
Pharyngeal oedemaRespiratory, thoracic and mediastinal disorders1/20/20/20/20/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)VX-561 20 mgVX-561 100 mgVX-561 150 mgPlaceboIvacaftorTotal
Mean24.0 ± 1.4120.0 ± 1.4119.5 ± 2.1229.0 ± 2.8319.7 ± 0.5822.2 ± 4.00
Sex: Female, Male
Sex: Female, Male(Participants)VX-561 20 mgVX-561 100 mgVX-561 150 mgPlaceboIvacaftorTotal
Female212229
Male010012
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VX-561 20 mgVX-561 100 mgVX-561 150 mgPlaceboIvacaftorTotal
Hispanic or Latino000101
Not Hispanic or Latino2221310
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VX-561 20 mgVX-561 100 mgVX-561 150 mgPlaceboIvacaftorTotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White2222311
More than one race000000
Unknown or Not Reported000000
Sweat Chloride
Sweat Chloride(millimole per liter (mmol/L))VX-561 20 mgVX-561 100 mgVX-561 150 mgPlaceboIvacaftorTotal
Mean59.25 ± 16.61782.25 ± 27.93161.50 ± 32.52736.50 ± 29.69871.25 ± 37.83062.15 ± 27.355
08

Study locations

14 sites
  • University of Southern California
    Los Angeles, California, United States
  • Stanford Hospital
    Palo Alto, California, United States
  • Children's National Health
    Washington, District of Columbia, United States
  • University of Miami
    Miami, Florida, United States
  • Rush University
    Chicago, Illinois, United States
  • Indiana University
    Indianapolis, Indiana, United States
  • Boston Children's Hospital
    Boston, Massachusetts, United States
  • University of Massachusetts
    Worcester, Massachusetts, United States
  • Washington University
    Saint Louis, Missouri, United States
  • Atlantic Health
    Morristown, New Jersey, United States
  • New York Medical College
    Valhalla, New York, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio, United States
  • Nationwide Children's Hospital
    Columbus, Ohio, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Aug 2017, 8 months.

Results were first posted in Aug 2020, 3 years after primary completion. A results delay was requested in Aug 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2016
First posted
Nov 23, 2016
StartActual
Dec 2016
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Results delay requested
Aug 13, 2018
Results first posted
Aug 26, 2020
Last update
Aug 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02971839
Responsible party
Sponsor
First posted
Nov 23, 2016
Start date
Dec 2016
Primary completion
Aug 2017
Completion
Aug 2017
Results posted
Aug 26, 2020
Last update
Aug 26, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion